Fate Therapeutics Q4 revenue $1.7M, cash $316M; FT522 first patient dosed, FT825 study initiated

FATE THERAPEUTICS INC

2023-FY EPS reported -$1.64 revenue$63,533,000

Cash and investments $316.2M at Dec 31, 2023; Q4 GAAP operating expenses $49.8M (R&D $31.8M, G&A $17.9M).
Revenue $1.7M from Ono collaboration preclinical activities; no product revenue.
FT522 (CAR NK) first patient treated; Phase 1 includes ADR technology, regimen with/without chemo conditioning.
FT825/ONO-8250 (CAR T) Phase 1 started for solid tumors; HER2-targeted with novel synthetic controls.
CIRM awarded $7.9M grant for FT819 Phase 1 SLE study; study start-up at multiple U.S. sites.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

FATE THERAPEUTICS INC reported financial results for fourth quarter and full year ended December 31, 2023.

Period: fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 26, 2024, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

FATE THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-020123

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.